Latest Ratios: P/E Ratio 44.2x · EV/EBITDA 32.7x · ROE 24.8%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.1B | $1.3B | $703M | $604M | $357M | $582M | $284M | $287M | $296M | $178M | $133M |
| Enterprise Value | $1.0B | $1.2B | $651M | $556M | $302M | $522M | $236M | $246M | $268M | $159M | $115M |
| P/E Ratio → | 44.19 | 55.59 | 36.67 | 35.16 | 27.74 | 62.45 | 207.27 | 29.97 | 47.04 | 378.75 | 18.50 |
| P/S Ratio | 11.78 | 14.92 | 9.60 | 9.21 | 6.71 | 13.91 | 8.94 | 7.45 | 9.73 | 7.69 | 4.10 |
| P/B Ratio | 11.18 | 13.22 | 8.10 | 8.46 | 4.85 | 8.06 | 4.62 | 5.17 | 7.06 | 5.39 | 4.17 |
| P/FCF | 40.55 | 72.78 | 39.90 | 110.66 | 43.77 | 55.33 | 54.75 | 29.45 | 41.65 | 68.53 | 16.88 |
| P/OCF | 42.18 | 50.12 | 27.44 | 44.85 | 35.60 | 51.68 | 48.76 | 28.05 | 40.16 | 51.98 | 14.15 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 14.31 | 8.89 | 8.48 | 5.66 | 12.49 | 7.45 | 6.40 | 8.81 | 6.90 | 3.55 |
| EV / EBITDA | 32.67 | 43.91 | 28.58 | 26.74 | 18.51 | 46.53 | 405.47 | 24.92 | 37.73 | 61.44 | 10.33 |
| EV / EBIT | 38.28 | 42.29 | 26.82 | 25.59 | 18.65 | 53.10 | — | 28.51 | 43.27 | 114.12 | 10.53 |
| EV / FCF | — | 69.80 | 36.95 | 101.91 | 36.94 | 49.67 | 45.61 | 25.29 | 37.71 | 61.50 | 14.64 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 76.7% | 76.7% | 76.9% | 76.5% | 77.4% | 76.6% | 74.3% | 77.1% | 76.3% | 75.9% | 81.1% |
| Operating Margin | 31.2% | 31.2% | 30.0% | 30.6% | 29.3% | 23.5% | -2.4% | 22.5% | 19.7% | 5.6% | 33.6% |
| Net Profit Margin | 26.8% | 26.8% | 26.3% | 26.2% | 24.1% | 22.3% | 4.3% | 25.0% | 20.7% | 2.2% | 22.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 24.8% | 24.8% | 24.3% | 23.7% | 17.6% | 14.0% | 2.3% | 19.8% | 16.8% | 1.5% | 22.6% |
| ROA | 21.7% | 21.7% | 20.2% | 19.4% | 15.2% | 12.1% | 2.0% | 16.7% | 14.4% | 1.3% | 19.9% |
| ROIC | 50.2% | 50.2% | 56.4% | 72.2% | 76.7% | 55.2% | -3.9% | 44.9% | 31.4% | 6.7% | 61.3% |
| ROCE | 27.8% | 27.8% | 26.5% | 26.2% | 20.4% | 13.8% | -1.2% | 16.5% | 15.3% | 3.8% | 33.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.00 | 0.03 | 0.03 | 0.03 | 0.04 | 0.05 | — | — | — |
| Debt / EBITDA | — | — | 0.01 | 0.10 | 0.14 | 0.22 | 4.66 | 0.30 | — | — | — |
| Net Debt / Equity | — | -0.54 | -0.60 | -0.67 | -0.76 | -0.82 | -0.77 | -0.73 | -0.67 | -0.55 | -0.56 |
| Net Debt / EBITDA | -1.87 | -1.87 | -2.29 | -2.29 | -3.42 | -5.30 | -81.26 | -4.10 | -3.94 | -7.02 | -1.59 |
| Debt / FCF | — | -2.98 | -2.96 | -8.74 | -6.83 | -5.66 | -9.14 | -4.16 | -3.94 | -7.03 | -2.25 |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($51M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.98 | 7.98 | 8.84 | 4.65 | 9.06 | 11.18 | 12.96 | 10.06 | 9.50 | 8.61 | 9.33 |
| Quick Ratio | 6.84 | 6.84 | 7.62 | 3.87 | 8.43 | 10.54 | 12.16 | 9.44 | 8.63 | 7.58 | 8.27 |
| Cash Ratio | 5.03 | 5.03 | 6.14 | 3.05 | 6.78 | 9.16 | 10.57 | 7.89 | 7.33 | 6.46 | 7.01 |
| Asset Turnover | — | 0.77 | 0.74 | 0.71 | 0.62 | 0.50 | 0.45 | 0.58 | 0.63 | 0.59 | 0.87 |
| Inventory Turnover | 1.68 | 1.68 | 1.62 | 1.20 | 2.24 | 2.27 | 2.07 | 2.42 | 1.78 | 1.32 | 1.58 |
| Days Sales Outstanding | — | 59.52 | 52.61 | 68.06 | 90.90 | 44.84 | 52.65 | 69.11 | 50.48 | 59.76 | 42.41 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 1.4% | 1.2% | 1.9% | 2.2% | 3.5% | — | — | — | — | — | — |
| Payout Ratio | 66.9% | 66.9% | 71.1% | 76.9% | 97.9% | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.3% | 1.8% | 2.7% | 2.8% | 3.6% | 1.6% | 0.5% | 3.3% | 2.1% | 0.3% | 5.4% |
| FCF Yield | 2.5% | 1.4% | 2.5% | 0.9% | 2.3% | 1.8% | 1.8% | 3.4% | 2.4% | 1.5% | 5.9% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 1.0% | 7.5% |
| Total Shareholder Yield | 1.4% | 1.2% | 1.9% | 2.2% | 3.5% | 0.0% | 0.0% | 0.0% | 0.1% | 1.0% | 7.5% |
| Shares Outstanding | — | $13M | $13M | $13M | $13M | $13M | $12M | $12M | $12M | $12M | $12M |
Includes 30+ ratios · 14 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IRMD stock.
IRadimed Corporation's current P/E ratio is 44.2x. The historical average is 42.4x. This places it at the 50th percentile of its historical range.
IRadimed Corporation's current EV/EBITDA is 32.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 33.2x.
IRadimed Corporation's return on equity (ROE) is 24.8%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 20.5%.
Based on historical data, IRadimed Corporation is trading at a P/E of 44.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
IRadimed Corporation's current dividend yield is 1.42% with a payout ratio of 66.9%.
IRadimed Corporation has 76.7% gross margin and 31.2% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Key Metrics
Top Statement Risk
Launch-driven margin pressure and guidance credibility
Metrics are mathematically derived from official filings.
Premium Multiples Demand Sustained Compounding
Based on reported figures, IRMD trades at 49.3x trailing P/E and 36.9x EV/EBITDA, a premium that presumes its recurring disposable revenue can keep compounding despite recent quarterly growth volatility.
Compared with its own 2024 quarterly history, the multiple has not been supported by a matching acceleration in top-line growth, since year-over-year revenue growth fell to roughly 0.3% in Q2 2026 before recovering. The PEG of 0.67 appears low only if forward earnings growth proves durable, which the recent EPS miss makes less certain. Relative to the peer set, where several names carry negative earnings, the premium reflects investor willingness to pay for profitability rather than a cheap valuation on any absolute basis.
Structural Margins Anchored by Niche Pricing
Gross margin has held between roughly 74% and 78% across ten quarters, while net margin of 26.9% in Q3 2026 suggests the high-margin model is intact even after the Q2 2026 pressure point.
The narrow gross margin band indicates that pricing power in the MRI-compatible niche is stable rather than episodic, which supports treating gross margin as the most reliable indicator of earning power. Operating margin of 33.6% in Q3 2026 versus 31.2% in Q2 suggests operating leverage is real but uneven, likely reflecting launch costs for the 3870 platform. Investors should monitor whether the Q2 dip proves transitory or indicates that the next-generation product carries structurally higher expense intensity.
Returns Diluted by Idle Cash Balance
ROIC has oscillated between roughly 11% and 14% over the period, with the Q3 2026 reading of 14.2% suggesting returns remain solid but are partly suppressed by a large non-operating cash balance.
The ROE of 6.2% and ROA of 5.5% in Q3 2026 appear modest relative to the operating margin, which points to a balance sheet where cash accounts for a large share of total assets. This implies that the return metrics understate the economics of the operating business while still reflecting a conservative capital allocation stance. The ROIC trend has not clearly compounded, so the case for rising returns depends on the company deploying its cash productively, which the reported data does not yet demonstrate.
Working Capital Stable but Receivables Lumpy
Days sales outstanding has held near 50 to 56 days and inventory days near 51 to 63, while the cash conversion cycle has ranged from roughly 212 to 325 days, suggesting working capital is steady but sensitive to quarterly timing.
The consistency of DSO and DIO implies stable collection and inventory practices, yet the cash conversion cycle appears inflated mainly by the payables component, which has been reported as swinging between roughly 190 and 288 days. Because the payables-based figures are unusually large relative to the other drivers, the cycle may be more a function of how the supplied data is structured than of operational leverage over suppliers. Analysts should treat the CCC as a directional signal and verify the payables definition before drawing conclusions about supplier financing.
Liquidity Far Exceeds Operating Needs
A current ratio near 9.0 and quick ratio of 9.0 in Q3 2026, with no reported debt, suggest liquidity is abundant relative to the company's current obligations, though the excess cash may reflect limited deployment.
Because inventory is a small share of current assets, the quick and current ratios converge, indicating that liquidity does not depend on converting inventory under stress. Even under a severe demand shock, the reported cash position would appear sufficient to cover near-term obligations, though the supplied data does not disclose stress scenarios directly. The more relevant question for investors is whether management can deploy this liquidity into growth or returns, since an unusually large idle balance can weigh on per-share economics.
Return on Equity Misleads on a Cash-Heavy Balance Sheet
ROE and ROA appear depressed in part because roughly half of total assets sits in cash, so these ratios may understate the operating economics investors are paying for at a 49x P/E.
Applying ROE to a business where equity is dominated by idle cash compresses the metric and makes the company look less profitable than its 27% net margin implies. A more informative lens is ROIC on operating capital or after-tax operating income relative to invested operating assets, which better isolates the productivity of the core franchise. Investors should be cautious about inferring weak capital efficiency from ROE alone, since that conclusion reflects the balance sheet structure rather than the economics of the disposable revenue model.